Development of Precision Medicine-based Cholangiocarcinoma Treatment Platforms

Adjuvant chemotherapy is required for cholangiocarcinoma (CCA) patients after surgical treatment in order to increase the patient survival. The CASCAP program under the Cholangiocarcinoma Research Institute (CARI) is now running the clinical trial program entitled “A randomized controlled trial of gemcitabine alone versus gemcitabine plus cisplatin: an adjuvant chemotherapy after curative resection of cholangiocarcinoma or GeCiCCA.” In parallel to the clinical trial, we are now developing the platforms to serve the precision medicine-based cholangiocarcinoma treatment which included the Histoculture Drug-response Assay (HDRA), Patient-Derived Xenograft (PDX) and Patient-Derived organoids (PCO) system. Moreover, the Multi-Omics Analysis is also performed in order to find the biomarkers for predicting the drug response as well as the progression and recurrence status of individual CCA patients. This work is supported mainly by the Cholangiocarcinoma Screening and Care Program and Fluke Free Thailand Project under the Cholangiocarcinoma Research Institute and the Thailand Research Fund.